Direct Effects of Activation and Inhibition of the Coagulation System on the Atrial Fibrillation Substrate Is Anticoagulation Antiarrhythmic?∗ by Nattel, Stanley
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E VO L . 1 , N O . 5 , 2 0 1 6
ª 2 0 1 6 T H E A U T H O R . P U B L I S H E D B Y E L S E V I E R O N B E H A L F O F T H E A M E R I C A N
C O L L E G E O F C A R D I O L O G Y F O UN DA T I O N . T H I S I S A N O P E N A C C E S S A R T I C L E U N D E R
T H E C C B Y - N C - N D L I C E N S E ( h t t p : / / c r e a t i v e c o mm o n s . o r g / l i c e n s e s / b y - n c - n d / 4 . 0 / ) .
I S S N 2 4 5 2 - 3 0 2 X
h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c b t s . 2 0 1 6 . 0 5 . 0 0 6EDITORIAL COMMENTDirect Effects of Activation and Inhibition
of the Coagulation System on the
Atrial Fibrillation Substrate
Is Anticoagulation Antiarrhythmic?*Stanley Nattel, MDSEE PAGE 328A trial ﬁbrillation (AF) is a highly prevalentclinical problem that is becoming more com-mon with population aging, and presents a
broad range of therapeutic challenges (1,2).
An improved understanding of the underlying pa-
thophysiology is central to improving management
options for the arrhythmia (3).
The most signiﬁcant complication of AF is throm-
boembolism, particularly stroke (4). AF-related stroke
is effectively prevented by oral anticoagulation
(OAC), achieved traditionally by vitamin K antago-
nists (VKAs) such as warfarin, and more recently by
direct-acting agents (DOACs) such as the thrombin-
antagonist dabigatran and the Factor Xa (FXa) in-
hibitors rivaroxaban, apixaban, and edoxaban (4).
Because of the attendant bleeding risk, OAC therapy
has been targeted to patients with elevated stroke
risk, although with the reduced bleeding seen with
DOACs versus VKAs, the threshold for OAC therapy
has decreased and the emphasis has shifted to iden-
tifying true low-risk individuals who may safely be
managed without OAC (5).
It has long been known that thrombin possesses
proinﬂammatory effects mediated by protease-
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paper to disclose.thrombin and FXa have proﬁbrotic effects (7).
Furthermore, thrombin-inhibition has antiﬁbrotic
effects (8). Atrial ﬁbrosis is a major potential
contributor to the substrate for AF maintenance
(9,10), and therefore beyond its role in clotting, acti-
vated thrombin or FXa could contribute to the
progression of the AF substrate. Conversely, in-
hibitors of thrombin or FXa such as the DOACs could
have an AF-suppressing effect.
THROMBIN INHIBITION AND THE
AF SUBSTRATE IN A RAT MODEL
OF CARDIAC DYSFUNCTION
In this issue of JACC: Basic to Translational Science,
Jumeau et al. (11) study the role of thrombin signaling
in a rat model of cardiac dysfunction due to myocar-
dial infarction (MI) (11). MI was created by ligating the
left anterior descending coronary artery for 30 min,
followed by reperfusion. MI caused ventricular
dysfunction, enhanced thrombogenesis, atrial ﬁbrosis
and dilation, and an AF substrate (the duration ofinduced AF increased from approximately 3 s to
approximately 6 s, p ¼ 0.02) over a period of 4 weeks
to 8 weeks. Dabigatran or another direct-acting
thrombin inhibitor (DTI) suppressed these changes,
while attenuating the upregulation of a variety of
remodeling-related (connective tissue growth factor
[CTGF], brain natriuretic peptide [BNP], a-myosin
heavy chain [MHC]) and procoagulant (plasminogen
activator inhibitor [PAI]-1) factors/biomarkers. The
direct effects of thrombin were studied in rat atrial
explants, showing that it increases the expression of
BNP, a-MHC, PAI-1, and phosphorylated signal
TABLE 1 Summary of Studies Addressing the Role of Thrombin Activation and Anticoagulation in Atrial Electrophysiology and AF-Promoting Remodeling
First Author,
Year (Ref. #) Tissue Experiment Biochemical Effect(s) Remodeling Effects Electrophysiological Effect(s)
Bukowska, 2013 (15) Human atrium Exposure to Fxa Upregulation of PAR2, ICAM-1,
IL-8, PAI-1
NT NT
Tachypacing þ Fxa Upregulation PAR1/2, ICAM-1, IL-8,
PAI-1, LOX-1
NT NT
Fxa/TP þ RIVA or Effects blocked by RIVA NT NT
PAR1-blocker
Chang, 2012 (12) Rabbit PV Exposure in vitro NT NT Thrombin decreased PV automaticity
and APD
L-NAME, dabigatran or PAR-1
blocker attenuated effects
Chang, 2013 (14) Rabbit LA LA cells in vitro NT NT RIVA decreased APD and increased
diastolic tension
RIVA increased ICa,L and IKur, no
change in Ito
Spronk, 2016 (16) Rat atrial FBs Exposure in vitro Thrombin [P-Akt, pERK, TGFb, MCP1
expression
Thrombin enhanced 3H-proline
incorporation
Effects blocked by dabigatran and
PAR1 inhibitor
TG mice Procoagulant mice Atrial ﬁbrosis Atrial ﬁbrosis Increased AF inducibility and
duration
AF goats Nadroparin Decreased Fibrosis, aSMA
positive FBs
Decreased complexity of AF; AFCL
unchanged; ?AF duration
Jumeau, 2016 (11) MI rats DTI or PAR1 blocker
therapy
DTI suppressed CTGF, PAI-1
upregulation
DTI decreased BNP, aMHC
upregulation
DTI or PAR1 decreased
LA size
DTI decreased LA ﬁbrosis,
hypertrophy
AF promotion suppressed
Rat atria Thrombin, PAR1,
ROCK blocker
Thrombin increased BNP, aMHC, PAI-1,
pSTAT3
Thrombin effect blocked by PAR1,
ROCK blocker
AF ¼ atrial ﬁbrillation; APD ¼ action potential duration; BNP ¼ brain natriuretic peptide; DTI ¼ direct thrombin inhibitor; FB ¼ ﬁbroblast; FXa ¼ Factor Xa; ICa,L ¼ L-type Ca2þ current; ICAM ¼ intracellular
adhesion molecule; IKur ¼ ultrarapid delayed rectiﬁer Kþ current; IL ¼ interleukin; Ito ¼ transient outward Kþ current; LA ¼ left atrium; L-NAME ¼ N(G)-nitro-L-arginine methyl ester; LOX ¼ lysyl oxidase;
MCP ¼ monocyte chemoattractant protein; aMHC ¼ a myosin heavy chain; NT ¼ not tested; PAI ¼ plasminogen activator inhibitor; pAkt ¼ phosphorylated Akt; PAR ¼ protease-activated receptor; pERK ¼
phosphorylated extracellular signal-related kinase; pSTAT3 ¼ phosphorylated STAT3; PV ¼ pulmonary vein; RIVA ¼ rivaroxaban; ROCK ¼ Rho-associated coiled-coil kinase; SMA ¼ smooth muscle actin;
TGF ¼ transforming growth factor; TG ¼ transgenic; TP ¼ tachypacing.
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341transducer and activator of transcription-3, or STAT3
(pSTAT3), and that these effects are prevented by a
PAR-1 blocker and an inhibitor of Rho coiled-coil ki-
nase (ROCK) signaling. These results indicate a
contribution of activated thrombin to proﬁbrillatory
atrial remodeling post-MI and suggest that in addi-
tion to their anticoagulant effects DTIs may attenuate
the development of an AF-supporting substrate.
RELATIONSHIP TO OTHER STUDIES
IN THE LITERATURE
A range of other investigators have addressed the
effects of OACs on atrial electrophysiology and
remodeling, as summarized in Table 1. Chang et al.
(12) showed that thrombin decreases pulmonary vein
(PV) cellular automaticity and left-atrial (LA) action
potential duration (APD) while increasing PV trig-
gered activity, effects that were blocked bydabigatran, a PAR-1 blocker and N(G)-nitro-L-arginine
methyl ester (L-NAME) (a nitric oxide synthase in-
hibitor). An APD reduction should promote re-entry
circuits that maintain AF, whereas increased trig-
gered activity should enhance spontaneous AF-
initiation (13). In a follow-up study, the same in-
vestigators showed that rivaroxaban reduces LA APD
in rabbit LA-cells, while increasing L-type Ca2þ cur-
rent and ultrarapid delayed rectiﬁer Kþ current (14). If
applicable to man, these results would suggest that
thrombin promotes AF, an effect that can be pre-
vented by a DTI, but that rivaroxaban might be pro-
ﬁbrillatory. Bukowska et al. (15) showed that FXa
causes proinﬂammatory signaling in human atrial
tissue, upregulating PAR2, phosphorylated extracel-
lular signal-related kinase, intracellular adhesion
molecule (ICAM)-1, interleukin-8, and PAI-1. These
effects were enhanced by atrial tachypacing to mimic
the remodeling effects of AF and suppressed by PAR-1
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342or PAR-2 blockade. In a very recent study, Spronk
et al. (16) used several models to examine the po-
tential role of hypercoagulability and its suppression
in AF remodeling. They noted that in rat atrial ﬁbro-
blasts, thrombin enhances the expression of the pro-
ﬁbrotic factor transforming growth factor-b1 and the
proinﬂammatory substance monocyte chemo-
attractant protein-1 while enhancing 3H-proline up-
take, suggesting increased collagen production.
These actions were blocked by dabigatran and a PAR-1
blocker. In a transgenic mouse model with coagula-
tion enhanced by a thrombomodulin gene mutation,
atrial ﬁbrous-tissue content was increased and AF-
duration was enhanced, although the effects of anti-
coagulation do not appear to have been assessed. In a
goat model of persistent AF induced by prior elec-
trical AF-maintenance, the FXa inhibitor nadroparin
reduced thrombin generation and reduced AF
complexity, without affecting AF cycle length.
Changes in AF sustainability were not reported.
SYNTHESIS OF RESULTS TO DATE
Taken together, the available data suggest that the
thrombosis-promoting effect of AF may, in addition to
leading to thromboembolic events, contribute to the
ability of AF to cause electrical and structural changes
that favor its own maintenance and recurrence.
However, there are some aspects of the ﬁndings that
are unclear. Two studies suggest direct electrophysi-
ological effects of activated thrombin and OACs
(12,14). This action should lead to detectable clinical
electrophysiological and electrocardiogram changes
in AF populations, but these have not been reported.
Promotion of the AF substrate in association with
increased coagulation has been described in rodent
models. For one of these, reversal by DTI was shown
(11), but for the other, DOAC effects were apparently
not tested (16). AF-promoting effects have been
modest and reported only in rodent models. The
stimulation of proinﬂammatory and proﬁbrotic fac-
tors by activated thrombin and/or FXa seems to be a
fairly constant ﬁnding, as is its inhibition by DOACs.WHERE DO WE GO FROM HERE?
It will be very important to determine the relevance of
these ﬁndings to atrial electrophysiology and remod-
eling in man. The data indicating that thrombin
activation promotes atrial remodeling have been ob-
tained principally in speciﬁc rodent models and
in vitro cell systems (11,16) that cannot necessarily be
assumed to apply to clinical AF. Modern imaging
methods allow for the AF substrate to be quantiﬁed
(17); direct comparisons among matched patients tak-
ing various DOACs and VKA therapy, versus those not
on such therapy, should be possible. Of even greater
interest would be longitudinal studies on patients with
AF before and after initiation of a DOAC. Extensive
databases are available for patients randomized to
VKA versus DOAC therapy—these should be interro-
gated to identify any signal for antiarrhythmic actions
of DOACs. Finally, serious consideration should be
given to prospective randomized studies of DOAC
therapy versus placebo in paroxysmal AF patients at
lower risk of stroke than would presently be consid-
ered to require OAC treatment, in order to determine
whether OACs favorably inﬂuence the natural history
of AF progression. If they do, the stroke-risk threshold
for OAC treatment will certainly move even lower than
it is today, and a new and attractive treatment to
suppress AF will have been identiﬁed.
CONCLUSIONS
The study of Jumeau et al. (11) lends credence to the
idea that OACs may have beneﬁcial effects in AF that
go beyond simply preventing clot formation, to
inﬂuencing the natural history of the arrhythmia it-
self. If conﬁrmed clinically, such ﬁndings would be of
great practical importance.
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